Hakan Eminoğlu

Dr. Hakan Eminoğlu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
ADAli Durdu
Ali Durdu
UHUgur Hatipoglu
Ugur Hatipoglu
HEHakan Eminoğlu
Hakan Eminoğlu
Turgay UlasTurgay Ulas
Turgay Ulas
MDMehmet Sinan Dal
Mehmet Sinan Dal
FAFevzi Altuntas
Fevzi Altuntas
Mesenchymal stem/stromal cells (MSCs) exhibit broad differentiation capability and strong immunoregulatory potential mediated through intercellular communication and the release of diverse paracrine mediators. They represent a promising but still investigational therapeutic approach for managing complications associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). This review provides an updated synthesis of MSC biology, their bidirectional interaction with immune cells, and their functional contribution to the hematopoietic niche. It also evaluates current clinical evidence regarding the therapeutic roles of MSCs and MSC-derived extracellular vesicles (EVs) in acute and chronic graft-versus-host disease (aGVHD/cGVHD), as well as in poor graft function. Mechanistic insights encompass macrophage polarization toward an anti-inflammatory phenotype, inhibition of dendritic cell maturation, enhancement of regulatory T-cell expansion, and modulation of cytokine signaling pathways. Within the bone marrow milieu, MSCs contribute to stromal restoration and angiogenic repair. Recent phase II/III trials in steroid-refractory (SR)-aGVHD have demonstrated overall response rates ranging from 48 to 71%. Efficacy appears particularly enhanced in pediatric patients and with early MSC administration. Across studies, MSC therapy shows a favorable safety profile; however, heterogeneity in response and inconsistent survival outcomes remain notable limitations. For poor graft function, limited prospective studies indicate hematopoietic recovery following third-party MSC infusions, and combination approaches such as co-administration with thrombopoietin receptor agonists are under investigation. MSC-derived EVs emulate many immunomodulatory effects of their parental cells with a potentially safer profile, though clinical validation remains in its infancy. MSC-oriented interventions hold substantial biological and therapeutic promise, offering a favorable safety margin; however, clinical translation is hindered by product variability, suboptimal engraftment and persistence, and inconsistent efficacy across studies. Future directions should emphasize standardized manufacturing and potency assays, biomarker-driven patient and timing selection, optimized conditioning and dosing strategies, and the systematic appraisal of EV-based or genetically modified MSC products through controlled trials.

26 October 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
VDVehbi Demircan
Vehbi Demircan
KYKÜBRA YAZAR
KÜBRA YAZAR
HEHakan Eminoğlu
Hakan Eminoğlu
YKYAVUZ KATIRCILAR
YAVUZ KATIRCILAR
AKABDULLAH KARAKUS
ABDULLAH KARAKUS
MAMEHMET ORHAN AYYILDIZ
MEHMET ORHAN AYYILDIZ
Background/Objectives: Iron deficiency may be associated with alterations in systemic inflammatory activity and metabolic parameters. However, whether oral and intravenous (IV) iron replacement have different effects on inflammatory markers and serum uric acid remains unclear. We compared inflammatory and metabolic responses to oral and IV iron in premenopausal women with iron deficiency. Methods: This prospective observational study included 72 oral iron recipients, 77 IV iron recipients, and 76 healthy controls. Patients were reassessed at Day 30. The primary outcome was change in C-reactive protein (CRP); changes in erythrocyte sedimentation rate (ESR) and uric acid were secondary outcomes. Additional regressions used robust standard errors, adjusting for age, baseline hemoglobin, and baseline outcome values; the uric acid model additionally included baseline creatinine. Results: Baseline CRP and ESR were significantly higher in both iron-deficient groups than in controls (all Bonferroni-adjusted p < 0.001). The IV iron group had more severe baseline anemia than the oral iron group (median hemoglobin: 8.60 vs. 10.70 g/dL; Bonferroni-adjusted p < 0.001). Increases in hemoglobin, ferritin, and transferrin saturation over 30 days were greater with IV iron (all p < 0.001). Median CRP changes were −0.22 mg/L with IV iron and 0.07 mg/L with oral iron (unadjusted p = 0.041). However, multivariable regression with robust standard errors showed no statistically significant difference in Day 30 CRP after adjustment for age, baseline hemoglobin, and baseline CRP (IV minus oral: −1.585 mg/L; 95% CI, −3.261 to 0.091; p = 0.064; n = 149). The corresponding adjusted analysis showed lower Day 30 ESR with IV iron (−2.118 mm/h; 95% CI, −3.817 to −0.418; p = 0.015; n = 91). The adjusted serum uric acid difference, additionally accounting for baseline creatinine, was not statistically significant (0.389 mg/dL; 95% CI, −0.009 to 0.787; p = 0.055; n = 149). Conclusions: IV iron was associated with greater hematologic and iron-store repletion over 30 days. Adjusted comparisons showed no statistically significant differences in CRP or serum uric acid, whereas ESR was modestly lower with IV iron, with uncertain clinical significance. Nonrandomized treatment allocation and premedication restricted to the IV group preclude attributing these findings solely to iron administration.

19 September 2026 in Cancers
Verified
Journal Article
Open access
PDF file
UHUgur Hatipoglu
Ugur Hatipoglu
Mert SeyhanMert Seyhan
Mert Seyhan
HEHakan Eminoğlu
Hakan Eminoğlu
Turgay UlasTurgay Ulas
Turgay Ulas
MDMehmet Sinan Dal
Mehmet Sinan Dal
Background: Primary cutaneous lymphomas (PCLs) represent a heterogeneous group of extranodal non-Hodgkin lymphomas with distinct clinical, histological, and molecular profiles. Recent advancements in genomic profiling have led to significant revisions in diagnostic frameworks and therapeutic paradigms. Objective: This review aims to summarize the current landscape of primary cutaneous B-cell and T-cell lymphomas and lymphoproliferative disorders (LPDs), focusing on the diagnostic updates in the WHO 5th edition and the International Consensus Classification (ICC 2022), alongside evolving risk-adapted treatment strategies. Methods: A comprehensive review of the recent literature and major international consensus guidelines was conducted, evaluating diagnostic shifts, disease reclassifications, and novel therapeutic interventions across various PCL subtypes. Results: The latest WHO 5th and ICC 2022 classifications emphasize the clinical behavior of indolent entities, shifting terminology from “lymphoma” to “lymphoproliferative disorder” for conditions such as primary cutaneous acral CD8+ T-cell LPD and primary cutaneous CD4+ small/medium T-cell LPD to prevent overtreatment. Several previously provisional categories (e.g., primary cutaneous gamma/delta T-cell lymphoma and EBV-positive mucocutaneous ulcer) have achieved definitive diagnostic status. Parallel to these revisions, therapeutic management has shifted toward toxicity-reducing, risk-adapted strategies. For indolent subtypes, ultra-low-dose radiotherapy (4 Gy) and skin-directed therapies remain highly effective. In aggressive or refractory subtypes, such as Mycosis Fungoides and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT), precision oncology—utilizing targeted agents (e.g., brentuximab vedotin, mogamulizumab, lenalidomide, ibrutinib) and cellular/immunotherapies—is rapidly changing outcomes. Conclusions: Integrating the updated diagnostic classifications with modern risk-stratified and targeted treatment paradigms is crucial for optimizing clinical management and avoiding overtreatment in indolent PCLs while improving survival in aggressive subtypes.

19 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
VDVehbi Demircan
Vehbi Demircan
KYKÜBRA YAZAR
KÜBRA YAZAR
HEHakan Eminoğlu
Hakan Eminoğlu
YKYAVUZ KATIRCILAR
YAVUZ KATIRCILAR
AKABDULLAH KARAKUS
ABDULLAH KARAKUS
MAMEHMET ORHAN AYYILDIZ
MEHMET ORHAN AYYILDIZ
Background/Objectives: Iron deficiency may be associated with alterations in systemic inflammatory activity and metabolic parameters. However, whether oral and intravenous (IV) iron replacement have different effects on inflammatory markers and serum uric acid remains unclear. We compared inflammatory and metabolic responses to oral and IV iron in premenopausal women with iron deficiency. Methods: This prospective observational study included 72 oral iron recipients, 77 IV iron recipients, and 76 healthy controls. Patients were reassessed at Day 30. The primary outcome was change in C-reactive protein (CRP); changes in erythrocyte sedimentation rate (ESR) and uric acid were secondary outcomes. Additional regressions used robust standard errors, adjusting for age, baseline hemoglobin, and baseline outcome values; the uric acid model additionally included baseline creatinine. Results: Baseline CRP and ESR were significantly higher in both iron-deficient groups than in controls (all Bonferroni-adjusted p<0.001). The IV iron group had more severe baseline anemia than the oral iron group (median hemoglobin: 8.60 vs. 10.70 g/dL; Bonferroni-adjusted p<0.001). Increases in hemoglobin, ferritin, and transferrin saturation over 30 days were greater with IV iron (all p<0.001). Median CRP changes were −0.22 mg/L with IV iron and 0.07 mg/L with oral iron (unadjusted p=0.041). However, multivariable regression with robust standard errors showed no statistically significant difference in Day 30 CRP after adjustment for age, baseline hemoglobin, and baseline CRP (IV minus oral: −1.585 mg/L; 95% CI, −3.261 to 0.091; p=0.064; n=149). The corresponding adjusted analysis showed lower Day 30 ESR with IV iron (−2.118 mm/h; 95% CI, −3.817 to −0.418; p=0.015; n=91). The adjusted serum uric acid difference, additionally accounting for baseline creatinine, was not statistically significant (0.389 mg/dL; 95% CI, −0.009 to 0.787; p=0.055; n=149). Conclusions: IV iron was associated with greater hematologic and iron-store repletion over 30 days. Adjusted comparisons showed no statistically significant differences in CRP or serum uric acid, whereas ESR was modestly lower with IV iron, with uncertain clinical significance. Nonrandomized treatment allocation and premedication restricted to the IV group preclude attributing these findings solely to iron administration.

28 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ADAli Durdu
Ali Durdu
UHUgur Hatipoglu
Ugur Hatipoglu
HEHakan Eminoğlu
Hakan Eminoğlu
Turgay UlasTurgay Ulas
Turgay Ulas
MDMehmet Sinan Dal
Mehmet Sinan Dal
FAFevzi Altuntas
Fevzi Altuntas
Mesenchymal stem/stromal cells (MSCs) exhibit broad differentiation capability and strong immunoregulatory potential mediated through intercellular communication and the release of diverse paracrine mediators. These features render MSCs a promising therapeutic option for managing complications associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). This review provides an updated synthesis of MSC biology, their bidirectional interaction with immune cells, and their functional contribution to the hematopoietic niche. It also evaluates current clinical evidence regarding the therapeutic roles of MSCs and MSC-derived extracellular vesicles (EVs) in acute and chronic graft-versus-host disease (aGVHD/cGVHD) as well as in poor graft function. Mechanistic insights encompass macrophage polarization toward an anti-inflammatory phenotype, inhibition of dendritic cell maturation, enhancement of regulatory T-cell expansion, and modulation of cytokine signaling pathways. Within the bone marrow milieu, MSCs contribute to stromal restoration and angiogenic repair. Data from phase II/III clinical trials and real-world cohorts in steroid-refractory aGVHD consistently confirm the safety of MSC therapy, although response rates vary—typically higher in pediatric patients and when administered early—while survival outcomes remain inconsistent. For poor graft function, limited prospective studies indicate hematopoietic recovery following third-party MSC infusions, and combination approaches such as co-administration with thrombopoietin receptor agonists are under investigation. MSC-derived EVs emulate many immunomodulatory effects of their parental cells with a potentially safer profile, though clinical validation remains in its infancy. MSC-oriented interventions hold substantial biological and therapeutic promise, offering a favorable safety margin; however, clinical translation is hindered by product variability, suboptimal engraftment and persistence, and inconsistent efficacy across studies. Future directions should emphasize standardized manufacturing and potency assays, biomarker-driven patient and timing selection, optimized conditioning and dosing strategies, and the systematic appraisal of EV-based or genetically modified MSC products through controlled trials.